PCM
BLFS icon

Prelude Capital Management’s BioLife Solutions BLFS Stock Holding History

Prelude Capital Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,146
Closed -$262K – 1154
2025
Q2 		$262K Buy
+12,146
New +$274K 0.03% 672
2019
Q3 		– Sell
-248
Closed -$4K – 1714
2019
Q2 		$4K Sell
248
-4,584
-95% -$79.9K ﹤0.01% 1534
2019
Q1 		$86K Buy
4,832
+3,941
+442% +$62.7K ﹤0.01% 974
2018
Q4 		$11K Buy
891
+698
+362% +$8.34K ﹤0.01% 1354
2018
Q3 		$3K Buy
+193
New +$3.82K ﹤0.01% 1657

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Prelude Capital Management's BLFS Position: Q3 2025 in Review

Prelude Capital Management sold out of BioLife Solutions (BLFS) in Q3 2025, closing a stake of 12,146 shares — an estimated $262K sold.

Prelude Capital Management first reported a position in BLFS in Q3 2018 and held it in 5 quarters. The position peaked at $262K in Q2 2025. 192 funds tracked by Wall St. Rank hold BLFS as of Q3 2025.

  • Prelude Capital Management reported no remaining BioLife Solutions position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 12,146 BioLife Solutions shares in Q3 2025, an estimated $262K.
  • Prelude Capital Management first reported a position in BioLife Solutions in Q3 2018 and held it in 5 quarters.
  • Prelude Capital Management's BioLife Solutions position peaked at $262K in Q2 2025.
  • 192 funds tracked by Wall St. Rank held BioLife Solutions as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.